Placeholder Banner

BIO Statement on Lawsuit Over 340B Rebates

November 12, 2024

BIO strongly supports a manufacturer’s ability to use a 340B rebate as an appropriate option to make 340B pricing available to covered entities.

"Manufacturers should have the choice to effectuate 340B pricing in the manner they deem most efficient and appropriate under the statute," said BIO's EVP for Health and Policy Programs, Phyllis Arthur. "A 340B rebate is, and should be, among the legally permissible options. We strongly support efforts that could bring the type of transparency needed to protect the integrity of the program.”

A copy of BIO's prior letter to HRSA is available here: https://www.bio.org/letters-testimony-comments/bio-letter-hrsa-340b-rebate-model 

Discover More
July 17, 2024 – BIO President and CEO John F. Crowley today released the following statement after the U.S. Food & Drug Administration (FDA) announced a plan to establish a Rare Disease Innovation Hub that will utilize new and collaborative…
BIO President and CEO John F. Crowley today released the following statement after a bipartisan group of Senators, Sen. Bob Casey (D-PA), Sen. Markwayne Mullin (R-OK), Sen. Sherrod Brown (D-OH), and Sen. Susan Collins (R-ME), introduced the Creating…
Biotechnology Innovation Organization (BIO) is proud to conclude the 2024 BIO International Convention in San Diego, held last week June 3-6, 2024. 1,400 exhibitors and more than 19,500 attendees from 70 countries came together for four full days of…